MetaVia partners with Syntekabio to use AI for new DA-1241 indications

MetaVia Inc.

Collaboration leverages Syntekabio’s DeepMatcher platform to screen >1,700 protein targets for new DA-1241 indications.
Follows positive Phase 2a data in MASH; DA-1241 showed safety, hepatoprotective, and glucose-regulating effects.
No financial terms disclosed; initial insights expected later in 2025.
DA-1241 is a novel oral GPR119 agonist in clinical development for cardiometabolic diseases.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.